Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Annexon, Inc.

Clinical trials sponsored by Annexon, Inc., explained in plain language.

Annexon, Inc. ANNX NASDAQ

Develops complement-based therapies for autoimmune and neurodegenerative diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Not yet finished but already full! 1 Completed 1

New hope for GBS: Single-Dose drug enters final testing

Disease control Recruiting now

This study tests a single dose of tanruprubart (ANX005) in 30 adults and children with Guillain-Barré syndrome (GBS), a rare nerve disorder that causes weakness. The goal is to see how the drug works in the body, its early effects, and its safety. Participants must have GBS sympt…

Phase: PHASE3 • Sponsor: Annexon, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:39 UTC